Sjögren-Larsson syndrome (SLS) is an autosomal recessive neurocutaneous disorder caused by mutation in the ALDH3A2 gene that codes for human fatty aldehyde dehydrogenase (FALDH). Sjögren-Larsson syndrome patients lack FALDH, which catalyzes the oxidation of long-chain aliphatic aldehydes to fatty acids. The impaired FALDH activity leads to congenital ichthyosis, mental retardation and spasticity. The current lack of treatment is an impetus to develop gene therapy strategies by introducing functional FALDH into defective cells. We delivered human FALDH into keratinocytes of SLS patients using recombinant adeno-associated virus-2 vectors. Transduction of SLS keratinocytes resulted in an augmentation of FALDH activity comparable to phenotypically normal heterozygous carriers. Toxicity of long-chain aldehydes for FALDH-deficient cells decreased almost to the level of unaffected keratinocytes. Three-dimensional culture of corrected SLS keratinocytes revealed an ameliorated FALDH expression. These studies demonstrate the restoration of FALDH in human SLS cells supporting the concept of gene therapy as a potential future treatment option for SLS.
Introduction
Sjö gren-Larsson syndrome (SLS (MIM 270200)) is an autosomal recessive neurocutaneous disorder characterized by the clinical triad of ichthyosis, mental retardation and spasticity. 1 Although originally described in a cohort of inbred patients from the country of Vasterbotten in Northern Sweden, SLS is now known to occur worldwide at an estimated prevalence below 0.4 per 100 000.
The cutaneous symptoms are usually present at birth as a generalized ichthyosiform erythroderma, which brings the patient to medical attention. The more serious neurologic symptoms become evident within the first 3 years of life and together with the cutaneous changes prompt the diagnosis of SLS. Early signs of mental retardation and spasticity are a delay in achieving motor or verbal milestones. Most patients display an IQ of less than 60 and have severe speech defects. Spasticity slowly progresses and leads to di-or tetraplegia impairing walking and normal use of the upper extremities. Additional features are short stature, kyphoscoliosis, seizures and pathognemonic glistening white dots on the retina, among others.
Individuals with SLS have an absent or markedly reduced fatty alcohol oxidation owing to a genetic enzyme deficiency of fatty aldehyde dehydrogenase (FALDH) (EC 1.2.1.48; Enzyme Nomenclature Database), a major component of the microsomal fatty alcohol:nicotinamide-adenine dinucleotide (NAD+)-oxidoreductase complex (FAO). 2, 3 The corresponding gene ALDH3A2 has been linked to chromosome 17p11.2. 4 The full-length cDNA sequence for human FALDH contains an open reading frame of 1455 nucleotides encoding a protein of 485 amino acids (GenBank NM000382). 5 More than 70 mutations of diverse types have been identified in patients with SLS ranging from nucleotide substitutions to splicing defects and small insertions or deletions. [5] [6] [7] The gene defect causes tissue accumulation of free fatty alcohol, fatty aldehyde and related lipid metabolites that are thought to be responsible for the clinical features.
Therapy for SLS is so far purely symptomatic. Systemic retinoid acids or topical calcipotriol may improve skin symptoms, whereas both retinoids and zileuton, a newly developed leukotriene B4 synthesis inhibitor, have been shown to diminish the disturbing pruritus. 8, 9 The impact of a dietary management with the aim to reduce fatty alcohol production has been discussed controversially. 1, 10 No other therapeutic options, in particular causative ones, are available at present. Gene therapy has so far not been considered as a treatment option for SLS. We have recently shown that gene transfer of functional FALDH using adenoassociated virus-2 vectors (rAAV-2) can increase FALDH activity in a Chinese hamster ovary (CHO) cell line model resembling the gene defect of SLS. 11 In order to stepwise transfer this approach to humans, we herein performed transduction studies on human keratinocytes derived from an SLS patient.
Results
rAAV-2 vector-mediated transfer of functional FALDH resulted in an augmentation of FALDH activity in SLS keratinocytes to a level comparable to those of phenotypically normal heterozygous carriers A rAAV-2 vector was constructed, which contained the full-length human FALDH cDNA under control of an CMV promoter (rAAV-2/C-FALDH) (Figure 1 ). This vector has previously been tested for functionality in a CHO cell line model of SLS. 11 Primary keratinocytes from a patient with SLS (SLS keratinocytes) were isolated and cultured as described previously. 12 The diagnosis of SLS has been confirmed by mutational analysis (exon 6: Ala301Pro and nt906delT; exon 9: nt1297delGA) and by a marked reduction of the FALDH activity as measured in fibroblasts by two independent laboratories (WB Rizzo, Richmond, VA, USA and RJA Wanders, Amsterdam, The Netherlands). We in addition measured FALDH activity in cultured SLS keratinocytes and found consistent data evident by a reduction of FALDH activity below 15% of the level measured in keratinocytes derived from unaffected probands ( Figure 2 ). To determine if the impaired FALDH activity could be restored after gene transfer of the functional FALDH gene, SLS keratinocytes were transduced with rAAV-2/C-FALDH vectors and FALDH activity was measured approximately 4 weeks thereafter. Compared to untransduced or mock-transduced SLS keratinocytes, FALDH-transduced SLS keratinocytes revealed an average of fivefold increase in FALDH activity up to a level of 60-70% of normal keratinocytes ( Figure 2 ). As some heterozygous carriers of SLS display a partial enzyme deficiency with an activity between 50 and 60% of normal without the manifestation of an altered phenotype, 2, 13 this range of activity may result in a clinical benefit for homozygous SLS patients.
FALDH gene transfer stabilized cell resistance to long-chain aldehydes After restoring the FALDH activity in SLS keratinocytes, we wished to determine if such gene-corrected cells are resistant to long-chain aldehydes. It is known that exogenous long-chain aldehydes like octadecanal (C-18) are highly toxic for in vitro-cultured FALDH-defective cells.
14 This could be reconfirmed for human keratinocytes incubated for 20 h with 60 mM octadecanal. A cytotoxicity assay revealed only 17% survivors of SLS keratinocytes in comparison to more than 91% of healthy keratinocytes ( Figure 3 ). Following FALDH gene transfer, SLS keratinocytes regained resistance to long-chain aldehydes with 84% surviving cells. The mock-transduced SLS keratinocytes revealed 29% survivors, which for unknown reasons was slightly higher than the nontransduced SLS keratinocytes. Thus, gene transfer of FALDH stabilized resistance of SLS kerationcytes to long-chain aldehydes.
Restoration of FALDH in a three-dimensional SLS skin equivalent model
Next, we wished to determine whether FALDH can be restored in a three-dimensional skin equivalent model by reconstituting human epidermis on de-epidermized dermis. 15 Skin equivalents were regenerated from FALDH-transduced and untransduced SLS kertinocytes and normal control keratinocytes. In biopsies from SLS patients, it has been shown that enzyme histochemistry for the demonstration of hexanol dehydrogenase activity gives complementary results to FALDH biochemical Gene therapy for Sjögren-Larsson syndrome S Haug and M Braun-Falco assays. 16, 17 Using this method, normal epidermis turns black, with the highest intensity at the basal layer (Figure 4d ), whereas in SLS, there is a marked reduction or absence of activity in the epidermis (Figure 4e) . This difference could be demonstrated on skin equivalents of normal and SLS keratinocytes. After gene transfer, it was possible to demonstrate in situ the restoration of FALDH activity by an increase in black discoloration (Figure 4f) .
Although the evaluation of the morphologic appearance of skin equivalents is hampered by a certain variability even within a single experiment, we had the impression that the thickness of the stratum corneum was more pronounced in skin equivalents from SLS keratinocytes (Figure 4b ) (corresponding to the clinical symptom of ichthyosis) than from normal keratinocytes ( Figure 4a ) and that the thickness was focally reduced in skin equivalents from FALDH-transduced SLS keratinocytes ( Figure 4c ). As this morphologic assessment is rather speculative, it needs a re-evaluation in an appropriate animal model.
Discussion
In the present study, we have investigated the ability to restore an FALDH gene defect in human cells derived from SLS patients by gene transfer of functional FALDH using rAAV-2 vectors. Vectors based on adeno-associated virus of several serotypes have gained increasing interest over the last years. 18 Among them, rAAV-2 is the most frequently utilized serotype, already under review in human gene therapy trials. 19, 20 rAAV-2 vectors offer several attractive features, such as (i) their apparent lack of pathogenicity, (ii) their low immunogenicity, (iii) their potential to transduce and integrate into a wide variety of dividing and non-dividing cells, both in vitro and in vivo, and (iv) their long-term, sustained expression of transgenes. rAAV-2 may be a promising vector particularly for SLS gene therapy, as they are able to transduce keratinocytes as well as neuronal cells, 12, 19, 21 which both resemble the predominantly affected cell types in SLS.
Although the most reliable study type to demonstrate the restoration of a genetic enzyme deficiency after gene transfer would be an in vivo setting, the present study has to be performed in vitro owing to the current lack of an appropriate animal model resembling SLS. Therefore, we decided to choose primary human keratinocytes derived from an SLS patient as the most reliable target to get closer to the human situation. Within this system, it was possible to demonstrate an augmentation of FALDH activity in SLS keratinocytes to a level comparable to the one of heterozygous carriers of the FALDH gene defect, who are phenotypically normal. The achieved increase of 60-70% of normal activity was most likely owing to an incomplete transduction of affected cells, as previous transduction studies using the same method have shown a stable transduction rate of approximately 10-14% of human keratinocytes over several weeks. 21 Therefore, one may assume that a more potent transduction would result in an even higher increase in FALDH activity. FALDH transduced SLS keratinocytes regained resistance for long-chain aldehydes, which are otherwise toxic for FALDH-deficient cells. This is an interesting phenomenon, as it may allow the speculation that FALDH transduced SLS cells may have a growth or survival advantage over defective cells. In a living organism, where long-chain aldehydes have to be constantly metabolized, the regain of resistance for long-chain aldehydes may function like an internal selection procedure for transduced cells. We were also able to demonstrate the re-expression of FALDH in a skin equivalent model. Unfortunately, this model, at least in our hands and with cautious interpretation, does not allow a trustworthy evaluation of the morphologic appearance of epidermal changes. Although we saw in some experiments a hyperkeratosis of the stratum corneum in SLS equivalents consisting with the histologic feature of ichthyosis and a reduced thickness of the stratum corneum in transduced SLS equivalents, this was not repeatedly the case. For a reliable morphologic evaluation, a transgenic mouse model for SLS is desirable. Blue-black formazan deposition as a sign of hexanol dehydrogenase activity corresponding to FALDH was intensive on sections of normal skin equivalents (d) and was markedly reduced or almost absent in SLS skin equivalents (e). Following FALDH gene transfer in SLS keratinocytes, tissue sections of reconstituted skin equivalents revealed an increase in formazan deposition (f). Tissue sections at Â 200 magnification of one out of two independent experiments are shown.
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Nevertheless, our data indicate that gene augmentation is a feasible future therapeutic approach for SLS. Before this gene therapy may be applicable to humans, there remain some important tasks to be answered first. The skin has been denoted as an ideal target tissue for gene therapy of inherited skin as well as systemic diseases owing to the presence of keratinocyte stem cells that are responsible for constant epidermal tissue renewing and thus required for sustained transgene expression. 22 Even rAAV-2 vectors can successfully target keratinocyte stem cells, 21 it has to be questioned whether the correction of skin cells can influence the neurological symptoms by lowering the systemic load of accumulated fatty aldehydes. It is supportive in this regard, that the concept of using genetically engineered skin as a 'metabolic sink' for systemic detoxification has already been shown in several diseases, such as phenylketonuria and gyrate atrophy. 23 Alternative strategies would be the direct targeting of neuronal tissue or the systemic distribution of FALDH after intramuscular gene transfer, the latter being already under clinical investigation for the treatment of hemophilia. 20 To address theses topics, it is currently paramount to develop a transgenic animal model for SLS that allows the assessment of morphologic skin changes as well as neurological symptoms. Unfortunately, the development of such a mouse model will probably be hampered by neonatal death of the transgenic mice. This was the case in transgenic mice with a disruption of the fatty acid transport protein 4, which developed a lethal, hyperkeratotic dermopathy, 24 and also in mouse models mimicking recessive congenital ichthyosis or Netherton's syndrome. 25, 26 An alternative would be a xenotransplantation of human SLS keratinocytes onto nude mice, but in this model the influence of the endogenous murine FALDH on the human SLS keratinocytes has to be evaluated first.
In conclusion, the data presented in this paper may provide a first basis for therapeutic gene transfer in SLS and offer a rationale to further pursue this approach.
Materials and methods

Cell culture
Human primary SLS keratinocytes were isolated from a +6 mm punch biopsy derived from an SLS patient after informed consent had been given; normal keratinocytes came from circumcised foreskin (provided by Dr Thomas A Angerpointer, Pediatric Surgery Practice, Munich, Germany). The specimens were processed using a standard protocol as previously described in detail. 12, 21 Cells were maintained in serum-free KSFM medium (GibcoBRL, Eggenstein, Germany) supplemented with 50 mg/ml bovine pituitary gland extract (Gibco), 10 ng/ ml epidermal growth factor (EGF) (Gibco), 100 U/ml penicillin (Biochrom, Berlin, Germany) and 100 mg/ml streptomycin (Biochrom) in the absence of a feeder layer, at 371C in a humidified atmosphere of 5% CO 2 and 95% air. Media were renewed every 2-3 days.
Expression vector construction
The rAAV-2-based gene transfer vector pTR-UF (kindly provided by Dr RJ Samulski, University of North Carolina, USA) contained the inverted terminal repeats (ITRs) of AAV-2, which are the minimal viral DNA sequences necessary in trans for the production of recombinant vector particles. 24 Between the ITRs, an expression cassette has been inserted containing the fulllength cDNA of the functional human FALDH (kind gift of Dr WB Rizzo, Medical College of Virginia, USA), 5 driven by a cytomegalovirus immediate-early promoter and terminated by an SV40 late polyadenylation signal. This construct was named pTR-UF/C-FALDH ( Figure  1) . 11 Vector plasmid pTR-UF/C-GFP, previously described in detail, 21 was used as a control, containing the cDNA of green fluorescent protein (Stratagene, La Jolla, CA, USA) within the same construct instead of FALDH.
rAAV-2 vector production and gene transfer
Preparation of rAAV-2 vector particles was performed by three-plasmid transient co-transfection of human 293 cells using a standard protocol described by Xiao et al.
27
Besides pTR-UF/C-FALDH or pTR-UF/C-GFP, packaging plasmid pRC containing the genes for AAV-2 replication (Rep) and -capsid (Cap) proteins, 12 and plasmid pXX6 containing adenovirus helper functions (also provided by Dr Samulski) were used. 27 After purification by ammonium sulfate precipitation and iodixanol gradient centrifugation, 28 the resulting titers were typically between 8 Â 10 10 and 6 Â 10 11 physical particles/ml as determined by dot blot analysis. rAAV-2 transduction was performed as described previously at 70-80% confluence after a 2 h pretreatment with 100 mM AG1478 followed by an incubation with fresh EGF-free KFSM medium containing 50 ml vector lysate. 21 After 18 h, the viral supernatant was removed, cells were washed twice and expanded under normal conditions.
Fatty aldehyde dehydrogenase activity assay
Fatty aldehyde dehydrogenase activity was assayed fluorometrically by measuring the fatty aldehyde-dependent production of NADH using octadecanal as substrate according to a standard protocol adapted from Rizzo et al.
2,29 C-18 aldehyde octadecanal was synthesized with 97% purity at the Biochemical Institute for Environmental Carcinogenes, University of Hamburg, Germany. Nearly confluent cell cultures were washed twice with ice-cold phosphate-buffered saline (PBS; Biochrom), trypsinized with 0.05% trypsine (w/v) and 0.02% (w/v) EDTA in PBS and pelleted by centrifugation at 300 g for 10 min, washed again with PBS and resuspended in 1 ml of homogenization buffer (25 mM Tris-HCl, pH 8.0, 0,25 M sucrose, 0.1% Triton X-100). Cell suspension was homogenized with 40 up and down strokes in a manual glass Teflon homogenizer after Tenbroeck (Wheaton Science Products, Millville, NJ, USA). An aliquot of each homogenate was removed for determination of protein content by a modified method of Lowry using a commercial available kit (BCA-Protein Assay, Pierce, Rockford, IL, USA). The remaining homogenates were either immediately further processed or stored at À701C. Frozen cell homogenates were thawed on ice and sonicated for 30 s in a sonic water bath (Sonorex super RK103H, Bandelin, Berlin, Germany) before assays.
Reaction was performed in 50 mM glycine-NaOH buffer, pH 9.0, 10 mM pyrazole, 0.2 mg/ml fatty acidfree BSA and 1.5 mM NAD + (Sigma, Munich, Germany). A 150 mg portion of cell homogenate was assayed in a Gene therapy for Sjögren-Larsson syndrome S Haug and M Braun-Falco final volume of 800 ml. The reactions were initiated by the addition of the aldehyde substrate (160 mM octadecanal dissolved in ethanol) and monitored for 30 min using a Varian Cary Eclipse fluorescence spectrometer (Varian, Palo Alto, CA,USA) at an excitation wavelength of 356 nm and emission wavelength of 460 nm. The aldehyde-dependent activity was calculated by subtracting the change in fluorescence measured in the absence of aldehyde (control containing only ethanol as substrate) from that measured in the presence of aldehyde.
Aldehyde cytotoxicity assay
Cytotoxicity was measured according to the method described by James and Zoeller. 14 A total of 500 cells, either SLS keratinocytes transfected with FALDH or GFP or normal keratinocytes, were plated onto 96-well plates and allowed to grow for 24 h. Cells were then incubated with 60 mM octadecanal in fully supplemented media for 20 h. Thereafter, cells were washed twice with PBS and cultured under optimal conditions for another 5-7 days. Cytotoxicity was measured by a colorimetric assay using sulforhodamin B (Sigma) for the detection of living cells. The optical density was determined in a computerinterfaced 96-well microtiter plate reader at 564 nm. Values per experiment are expressed as means of triplicates.
Hexanol dehydrogenase enzyme histochemistry
Hexanol dehydrogenase activity was demonstrated by blue-black formazan deposition on 12 mm sections cut from snap-frozen skin equivalents as described previously. 16, 17 The sections were defatted in cold (41C) acetone for 5 min, dried rapidly in an air stream and incubated at 371C for 90 min in a mixture composed of 0.1 ml of 1 M neutralized hexanol (Sigma), 2 mg NAD and 1 ml dehydrogenase medium (made from 5 ml of 0.05 M Tris-HCl buffer pH 7.4; 5 mg of MTT (Sigma) in 5 ml distilled water; 1 ml of 0.5 M cobaltous chloride; 7 ml distilled water).
